MAPK1 and cancer: These findings may also contribute to our understanding of the development or growth requirements of monocytic forms of myeloid malignancies and may lead to new therapeutic targets, since ERK signaling is known to contribute to cancer growth, and inhibitors of members of the MAPK cascade are in development for solid tumors [32, 33].